EGFR and lung adenocarcinoma: SEMA7A drives breast cancer progression through pleiotropic effects, inhibition of mesenchymal factors, and promotion of macrophage-mediated lymphatic remodeling.25–28 In EGFR-mutant lung adenocarcinoma cells, SEMA7A induces EGFR-TKI resistance through ERK activation and apoptosis inhibition.29 Few studies have investigated the mechanism of SEMA7A in the initiation and progression of HNSCC.